Two Sigma Investments
ALLO icon

Two Sigma Investments’s Allogene Therapeutics ALLO Stock Holding History

Two Sigma Investments’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.1M Buy
5,375,456
+1,952,015
+57% +$3.91M 0.01% 1226
2025
Q4 		$4.69M Buy
3,423,441
+39,797
+1% +$52.5K 0.01% 1770
2025
Q3 		$4.2M Buy
3,383,644
+1,770,419
+110% +$2.11M 0.01% 1594
2025
Q2 		$1.82M Sell
1,613,225
-461,874
-22% -$614K ﹤0.01% 1897
2025
Q1 		$3.03M Sell
2,075,099
-637,040
-23% -$1.2M 0.01% 1452
2024
Q4 		$5.78M Sell
2,712,139
-85,831
-3% -$212K 0.01% 1020
2024
Q3 		$7.83M Sell
2,797,970
-162,703
-5% -$434K 0.02% 864
2024
Q2 		$6.9M Buy
2,960,673
+1,049,335
+55% +$3.1M 0.02% 868
2024
Q1 		$8.54M Sell
1,911,338
-403,203
-17% -$1.68M 0.02% 714
2023
Q4 		$7.43M Buy
2,314,541
+1,014,320
+78% +$2.88M 0.02% 802
2023
Q3 		$4.12M Sell
1,300,221
-652,559
-33% -$2.86M 0.01% 998
2023
Q2 		$9.71M Buy
1,952,780
+76,031
+4% +$411K 0.02% 656
2023
Q1 		$9.27M Buy
1,876,749
+265,497
+16% +$1.7M 0.03% 616
2022
Q4 		$10.1M Buy
1,611,252
+778,288
+93% +$7.21M 0.03% 550
2022
Q3 		$9M Buy
832,964
+673,886
+424% +$9.16M 0.03% 526
2022
Q2 		$1.81M Sell
159,078
-795,086
-83% -$7.06M 0.01% 1252
2022
Q1 		$8.69M Buy
954,164
+764,373
+403% +$7.96M 0.03% 664
2021
Q4 		$2.83M Buy
+189,791
New +$3.35M 0.01% 1613
2021
Q3 		– Sell
-31,359
Closed -$818K – 4203
2021
Q2 		$818K Sell
31,359
-161,179
-84% -$4.6M ﹤0.01% 2659
2021
Q1 		$6.8M Sell
192,538
-151,086
-44% -$5.1M 0.02% 888
2020
Q4 		$8.67M Sell
343,624
-21,024
-6% -$685K 0.02% 658
2020
Q3 		$13.8M Buy
364,648
+111,255
+44% +$4.19M 0.05% 408
2020
Q2 		$10.8M Buy
+253,393
New +$9.16M 0.05% 365

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Two Sigma Investments's ALLO Position: Q1 2026 in Review

Two Sigma Investments increased its Allogene Therapeutics (ALLO) stake by 57% in Q1 2026, buying an estimated $3.91M and bringing the position to 5,375,456 shares worth $13.1M. The position accounts for 0.01% of the portfolio, ranked #1226.

Two Sigma Investments first reported a position in ALLO in Q2 2020 and has held it in 23 quarters since. The position peaked at $13.8M in Q3 2020. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Two Sigma Investments held 5,375,456 shares of Allogene Therapeutics worth $13.1M as of Q1 2026.
  • Two Sigma Investments bought 1,952,015 Allogene Therapeutics shares in Q1 2026, an estimated $3.91M.
  • Allogene Therapeutics made up 0.01% of Two Sigma Investments's portfolio in Q1 2026, its #1226 holding.
  • Two Sigma Investments first reported a position in Allogene Therapeutics in Q2 2020 and has held it in 23 quarters since.
  • Two Sigma Investments's Allogene Therapeutics position peaked at $13.8M in Q3 2020.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.